TherapeuticsMD, Inc. (TXMD)
USD 0.98
(11.61%)
USD 0.98
(11.61%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.67 Million USD | 112.55% |
| 2022 | -29.3 Million USD | -122.34% |
| 2021 | 131.21 Million USD | -20.9% |
| 2020 | 165.88 Million USD | 286.23% |
| 2019 | 42.94 Million USD | 148.68% |
| 2018 | -88.23 Million USD | 30.6% |
| 2017 | -127.13 Million USD | 3.34% |
| 2016 | -131.53 Million USD | -103.28% |
| 2015 | -64.7 Million USD | -25.98% |
| 2014 | -51.36 Million USD | 5.22% |
| 2013 | -54.19 Million USD | -2762.05% |
| 2012 | 2.03 Million USD | 0.6% |
| 2011 | 2.02 Million USD | 169.08% |
| 2010 | 752.03 Thousand USD | 34.79% |
| 2009 | 557.93 Thousand USD | 1125.26% |
| 2008 | -54.41 Thousand USD | 86.68% |
| 2007 | -408.63 Thousand USD | 58.54% |
| 2006 | -985.72 Thousand USD | -20.15% |
| 2005 | -820.42 Thousand USD | -218.41% |
| 2004 | -257.66 Thousand USD | -66.79% |
| 2003 | -154.49 Thousand USD | 51.18% |
| 2002 | -316.47 Thousand USD | 6.61% |
| 2001 | -338.87 Thousand USD | -76.83% |
| 2000 | -191.63 Thousand USD | -232.03% |
| 1999 | -57.71 Thousand USD | -735.99% |
| 1998 | 9075.00 USD | 105.44% |
| 1997 | -166.88 Thousand USD | 0.0% |
| 1996 | - USD | -100.0% |
| 1995 | 12.06 Thousand USD | 162.25% |
| 1994 | -19.38 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 3.46 Million USD | -5.82% |
| 2024 Q2 | 2.36 Million USD | -31.84% |
| 2023 Q2 | -5.34 Million USD | 38.4% |
| 2023 FY | 3.67 Million USD | 112.55% |
| 2023 Q1 | -8.67 Million USD | 70.41% |
| 2023 Q3 | -1.96 Million USD | 63.27% |
| 2023 Q4 | 3.67 Million USD | 287.46% |
| 2022 Q4 | -29.3 Million USD | -138.84% |
| 2022 Q3 | 75.45 Million USD | 2.55% |
| 2022 Q2 | 73.58 Million USD | -59.51% |
| 2022 FY | -29.3 Million USD | -122.34% |
| 2022 Q1 | 181.73 Million USD | 38.51% |
| 2021 Q2 | 82.21 Million USD | 49.81% |
| 2021 FY | 131.21 Million USD | -20.9% |
| 2021 Q3 | 90.12 Million USD | 9.61% |
| 2021 Q1 | 54.88 Million USD | -66.92% |
| 2021 Q4 | 131.21 Million USD | 45.59% |
| 2020 Q2 | 139.26 Million USD | 66.06% |
| 2020 Q1 | 83.86 Million USD | 95.27% |
| 2020 Q3 | 166.32 Million USD | 19.43% |
| 2020 Q4 | 165.88 Million USD | -0.26% |
| 2020 FY | 165.88 Million USD | 286.23% |
| 2019 Q2 | 13.73 Million USD | 129.44% |
| 2019 FY | 42.94 Million USD | 148.68% |
| 2019 Q1 | -46.65 Million USD | 47.12% |
| 2019 Q4 | 42.94 Million USD | -11.5% |
| 2019 Q3 | 48.53 Million USD | 253.29% |
| 2018 Q2 | -81.24 Million USD | 24.32% |
| 2018 Q3 | -116.73 Million USD | -43.69% |
| 2018 Q4 | -88.23 Million USD | 24.42% |
| 2018 Q1 | -107.34 Million USD | 15.56% |
| 2018 FY | -88.23 Million USD | 30.6% |
| 2017 FY | -127.13 Million USD | 3.34% |
| 2017 Q4 | -127.13 Million USD | 14.27% |
| 2017 Q1 | -113.52 Million USD | 13.69% |
| 2017 Q2 | -96.47 Million USD | 15.02% |
| 2017 Q3 | -148.29 Million USD | -53.71% |
| 2016 FY | -131.53 Million USD | -103.28% |
| 2016 Q1 | -182.09 Million USD | -181.42% |
| 2016 Q2 | -166.53 Million USD | 8.55% |
| 2016 Q3 | -147.53 Million USD | 11.41% |
| 2016 Q4 | -131.53 Million USD | 10.84% |
| 2015 Q2 | -67.24 Million USD | 26.63% |
| 2015 Q3 | -81.12 Million USD | -20.64% |
| 2015 Q4 | -64.7 Million USD | 20.24% |
| 2015 Q1 | -91.65 Million USD | -78.46% |
| 2015 FY | -64.7 Million USD | -25.98% |
| 2014 Q2 | -35.55 Million USD | 21.7% |
| 2014 FY | -51.36 Million USD | 5.22% |
| 2014 Q1 | -45.4 Million USD | 16.21% |
| 2014 Q3 | -66.99 Million USD | -88.44% |
| 2014 Q4 | -51.36 Million USD | 23.34% |
| 2013 Q4 | -54.19 Million USD | 9.03% |
| 2013 FY | -54.19 Million USD | -2762.05% |
| 2013 Q3 | -59.57 Million USD | -73.0% |
| 2013 Q2 | -34.43 Million USD | 10.97% |
| 2013 Q1 | -38.67 Million USD | -2000.07% |
| 2012 Q2 | 1.81 Million USD | -46.05% |
| 2012 FY | 2.03 Million USD | 0.6% |
| 2012 Q1 | 3.36 Million USD | 66.31% |
| 2012 Q3 | 5.43 Million USD | 199.42% |
| 2012 Q4 | 2.03 Million USD | -62.56% |
| 2011 FY | 2.02 Million USD | 169.08% |
| 2011 Q4 | 2.02 Million USD | 460.92% |
| 2011 Q3 | 360.76 Thousand USD | 18.07% |
| 2011 Q2 | 305.54 Thousand USD | 28.38% |
| 2011 Q1 | 238 Thousand USD | -68.35% |
| 2010 Q2 | -3677.00 USD | -100.49% |
| 2010 FY | 752.03 Thousand USD | 34.79% |
| 2010 Q3 | -23.94 Thousand USD | -551.24% |
| 2010 Q4 | 752.03 Thousand USD | 3240.54% |
| 2010 Q1 | 751.95 Thousand USD | 34.77% |
| 2009 FY | 557.93 Thousand USD | 1125.26% |
| 2009 Q3 | 280.17 Thousand USD | 3571.38% |
| 2009 Q2 | -8071.00 USD | 71.13% |
| 2009 Q4 | 557.93 Thousand USD | 99.14% |
| 2009 Q1 | -27.95 Thousand USD | 48.63% |
| 2008 Q2 | -121.61 Thousand USD | 66.31% |
| 2008 Q1 | -360.98 Thousand USD | 11.66% |
| 2008 FY | -54.41 Thousand USD | 86.68% |
| 2008 Q4 | -54.41 Thousand USD | 14.79% |
| 2008 Q3 | -63.86 Thousand USD | 47.48% |
| 2007 Q3 | -1.12 Million USD | -7.43% |
| 2007 Q1 | -1.02 Million USD | -3.52% |
| 2007 Q2 | -1.05 Million USD | -2.99% |
| 2007 FY | -408.63 Thousand USD | 58.54% |
| 2007 Q4 | -408.63 Thousand USD | 63.81% |
| 2006 Q4 | -985.72 Thousand USD | -5.73% |
| 2006 Q3 | -932.33 Thousand USD | -34.44% |
| 2006 FY | -985.72 Thousand USD | -20.15% |
| 2006 Q2 | -693.49 Thousand USD | -17.95% |
| 2006 Q1 | -587.94 Thousand USD | 28.34% |
| 2005 Q4 | -820.42 Thousand USD | -76.46% |
| 2005 Q1 | -368.36 Thousand USD | -42.96% |
| 2005 FY | -820.42 Thousand USD | -218.41% |
| 2005 Q3 | -464.95 Thousand USD | -11.11% |
| 2005 Q2 | -418.44 Thousand USD | -13.6% |
| 2004 Q3 | -81.17 Thousand USD | 68.33% |
| 2004 Q1 | -230.01 Thousand USD | -48.89% |
| 2004 Q2 | -256.3 Thousand USD | -11.43% |
| 2004 FY | -257.66 Thousand USD | -66.79% |
| 2004 Q4 | -257.66 Thousand USD | -217.42% |
| 2003 Q3 | -263.09 Thousand USD | -15.14% |
| 2003 Q4 | -154.49 Thousand USD | 41.28% |
| 2003 Q2 | -228.49 Thousand USD | 22.47% |
| 2003 Q1 | -294.73 Thousand USD | 6.87% |
| 2003 FY | -154.49 Thousand USD | 51.18% |
| 2002 Q1 | -378.36 Thousand USD | -11.65% |
| 2002 Q4 | -316.47 Thousand USD | -18.5% |
| 2002 Q3 | -267.07 Thousand USD | -8.01% |
| 2002 Q2 | -247.26 Thousand USD | 34.65% |
| 2002 FY | -316.47 Thousand USD | 6.61% |
| 2001 Q4 | -338.87 Thousand USD | -25.86% |
| 2001 Q1 | -238.72 Thousand USD | -24.57% |
| 2001 FY | -338.87 Thousand USD | -76.83% |
| 2001 Q2 | -293.33 Thousand USD | -22.88% |
| 2001 Q3 | -269.24 Thousand USD | 8.21% |
| 2000 Q4 | -191.63 Thousand USD | -36.64% |
| 2000 Q3 | -140.24 Thousand USD | -42.16% |
| 2000 Q2 | -98.65 Thousand USD | -23.17% |
| 2000 Q1 | -80.09 Thousand USD | -38.78% |
| 2000 FY | -191.63 Thousand USD | -232.03% |
| 1999 Q4 | -57.71 Thousand USD | 0.0% |
| 1999 FY | -57.71 Thousand USD | -735.99% |
| 1998 FY | 9075.00 USD | 105.44% |
| 1997 FY | -166.88 Thousand USD | 0.0% |
| 1996 FY | - USD | -100.0% |
| 1995 FY | 12.06 Thousand USD | 162.25% |
| 1994 FY | -19.38 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -99.704% |
| Alpha Teknova, Inc. | 1.97 Million USD | -86.322% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 96.096% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 95.093% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 99.155% |
| Cosmos Health Inc. | 8.59 Million USD | 57.187% |
| Journey Medical Corporation | -9.7 Million USD | 137.882% |
| Embecta Corp. | 1.31 Billion USD | 99.72% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 99.198% |
| Dynavax Technologies Corporation | 106.63 Million USD | 96.551% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 102.811% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 99.15% |
| PainReform Ltd. | -7.95 Million USD | 146.264% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 123.525% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 123.525% |
| SCYNEXIS, Inc. | -19.35 Million USD | 119.008% |
| Safety Shot Inc | -2.28 Million USD | 261.007% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 139.004% |
| Procaps Group, S.A. | 242.93 Million USD | 98.486% |
| Theratechnologies Inc. | 24.87 Million USD | 85.212% |
| Harrow Health, Inc. | 116.41 Million USD | 96.841% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 245.952% |
| Biofrontera Inc. | 4.05 Million USD | 9.32% |
| DURECT Corporation | -7.65 Million USD | 148.053% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 110.97% |
| Cronos Group Inc. | -663.32 Million USD | 100.554% |
| OptiNose, Inc. | 58.06 Million USD | 93.666% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 99.41% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 125.24% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 170.921% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 75.501% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 157.833% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -3341.919% |
| Radius Health, Inc. | 359.28 Million USD | 98.976% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -1765.026% |
| ProPhase Labs, Inc. | 19.23 Million USD | 80.875% |
| Phibro Animal Health Corporation | 454.84 Million USD | 99.191% |
| Procaps Group S.A. | 242.93 Million USD | 98.486% |
| Alvotech | 1.06 Billion USD | 99.654% |
| Viatris Inc. | 17.13 Billion USD | 99.979% |
| Rockwell Medical, Inc. | 4.45 Million USD | 17.46% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 175.415% |
| SIGA Technologies, Inc. | -148.68 Million USD | 102.474% |
| Tilray Brands, Inc. | 158.97 Million USD | 97.686% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 96.983% |
| Shineco, Inc. | 29.29 Million USD | 87.443% |
| PetIQ, Inc. | 351.93 Million USD | 98.955% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 226.765% |
| Incannex Healthcare Limited | -5.48 Million USD | 167.056% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 97.926% |
| Alimera Sciences, Inc. | 55.3 Million USD | 93.35% |
| Silver Spike Investment Corp. | -32.61 Million USD | 111.278% |
| Assertio Holdings, Inc. | -32.52 Million USD | 111.307% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 347.058% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 172.682% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 176.402% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 144.78% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 12.782% |
| Hempacco Co., Inc. | 13.61 Million USD | 72.985% |
| Talphera, Inc. | -5.72 Million USD | 164.289% |
| Alvotech | 1.06 Billion USD | 99.654% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 48.523% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 103.803% |
| Currenc Group, Inc. | -16.57 Million USD | 122.193% |
| Kamada Ltd. | -46.43 Million USD | 107.921% |
| Indivior PLC | -33.95 Million USD | 110.833% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -1311.499% |
| Flora Growth Corp. | -713 Thousand USD | 615.849% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 144.78% |
| Evolus, Inc. | 63.7 Million USD | 94.227% |
| HUTCHMED (China) Limited | -197.45 Million USD | 101.863% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 99.232% |
| Akanda Corp. | 3.9 Million USD | 5.811% |